Literature DB >> 22433633

Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany.

Ulrike Braisch1, Martin Meyer, Martin Radespiel-Tröger.   

Abstract

As the prevalence of prostate cancer in Germany is increasing, the issue of subsequent primary cancer (SPC) becomes more relevant. The aim of this study was to estimate the risk and its changes over time of developing SPC among prostate cancer patients compared with the general male population in Bavaria, southern Germany. Utilizing data from the Population-Based Cancer Registry Bavaria, the risk of SPC was evaluated in 59 259 men with prostate cancer diagnosed between 2002 and 2008 who contributed 159 892 person-years. The relative and absolute risk of developing SPC were calculated using the standardized incidence ratio (SIR) and the excess absolute risk. Changes in the risk were examined by plotting the SIR and its 95% confidence interval against time after the diagnosis of prostate cancer. The overall risk of SPC was significantly increased by 14% compared with the general male population. With regard to specific cancer types, a significantly increased risk of SPC was found for the urinary bladder, kidney, pancreas, melanoma of skin, leukemia, myeloma, brain/nervous system, renal pelvis/ureter, thyroid, and the small intestine. The absolute risk of SPC for most cancer types, however, was below 10 cases per 10 000 person-years. A significantly decreased risk of SPC was found in the lung/bronchus and the liver. Although detection bias cannot be excluded as a contributing factor for our results, we recommend continuing follow-up care of prostate cancer patients particularly with respect to SPC of the urinary system as a precaution.

Entities:  

Mesh:

Year:  2012        PMID: 22433633     DOI: 10.1097/CEJ.0b013e328351c748

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  8 in total

1.  Personal history of prostate cancer and increased risk of incident melanoma in the United States.

Authors:  Wen-Qing Li; Abrar A Qureshi; Jing Ma; Alisa M Goldstein; Edward L Giovannucci; Meir J Stampfer; Jiali Han
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

2.  A Possible Association between Melanoma and Prostate Cancer. Results from a Case-Control-Study.

Authors:  Alina Goldenberg; Shang I Brian Jiang; Philip R Cohen
Journal:  Cancers (Basel)       Date:  2015-04-15       Impact factor: 6.639

3.  Incidence of second malignancies for prostate cancer.

Authors:  Mieke Van Hemelrijck; Anita Feller; Hans Garmo; Fabio Valeri; Dimitri Korol; Silvia Dehler; Sabine Rohrmann
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

4.  Melanoma of non-sun exposed skin in a man with previous prostate cancer: recognition of a recently confirmed association.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-02-22

Review 5.  Is there a role for IGF-1 in the development of second primary cancers?

Authors:  Thurkaa Shanmugalingam; Cecilia Bosco; Anne J Ridley; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

6.  A rare presentation of metastatic prostate cancer, initially a suspect for urothelial cell carcinoma of the ureter: a case report.

Authors:  Ho Seok Chung; Myung Soo Kim; Yang Hyun Cho; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Suk Hee Heo; Chan Choi
Journal:  BMC Urol       Date:  2017-05-26       Impact factor: 2.264

7.  Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.

Authors:  Chao-Yueh Fan; Wen-Yen Huang; Chun-Shu Lin; Yu-Fu Su; Cheng-Hsiang Lo; Chih-Cheng Tsao; Ming-Yueh Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

8.  Skin Melanoma and Subsequent Risk of Prostate Cancer: A Lithuanian Cancer Registry Study.

Authors:  Ausvydas Patasius; Vincas Urbonas; Giedre Smailyte
Journal:  Int J Environ Res Public Health       Date:  2019-10-15       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.